Yahoo · Sep 9, 2026
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
SAN ANTONIO, September 09, 2026--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.
NASDAQ · BIAFW
bioAffinity Technologies, Inc.
Healthcare · Medical - Diagnostics & Research
$0.24
Down-$0.31 (-56.65%)
Updated Sep 12, 2026, 4:51 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.05M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $0.05 – $0.98
- Volume
- 6.57K
- Avg. volume
- 7.53K
Price performance
BIAFW price history
1M range · 14 trading sessions · Daily adjusted prices
BIAFW closed at $0.24 after 14 trading sessions, up 217.87% for the selected period.
- Last close
- $0.24
- Period change
- +217.87%
- Period low
- $0.08
- Period high
- $0.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.215 | $0.48 | $0.215 | $0.2384 | 6.57K |
| Sep 10, 2026 | $0.62 | $0.62 | $0.55 | $0.55 | 3.87K |
| Sep 9, 2026 | $0.634 | $0.644 | $0.55 | $0.597 | 10.51K |
| Sep 8, 2026 | $0.98 | $0.98 | $0.55 | $0.597 | 48.45K |
| Sep 4, 2026 | $0.3542 | $0.79 | $0.3255 | $0.70 | 39.15K |
| Sep 3, 2026 | $0.2201 | $0.3911 | $0.2201 | $0.3911 | 33.83K |
| Sep 2, 2026 | $0.189 | $0.5533 | $0.189 | $0.22 | 119.88K |
| Sep 1, 2026 | $0.1881 | $0.2029 | $0.1101 | $0.16 | 17.27K |
| Aug 24, 2026 | $0.0751 | $0.0751 | $0.0751 | $0.0751 | 1.1K |
| Aug 21, 2026 | $0.09 | $0.135 | $0.075 | $0.1165 | 4.05K |
| Aug 20, 2026 | $0.0757 | $0.1043 | $0.0757 | $0.1043 | 1K |
| Aug 19, 2026 | $0.091 | $0.1245 | $0.0756 | $0.1245 | 1.08K |
| Aug 18, 2026 | $0.0901 | $0.13 | $0.0901 | $0.0904 | 6.04K |
| Aug 17, 2026 | $0.0645 | $0.075 | $0.0645 | $0.075 | 2.63K |
Latest BIAFW news
The latest Smart Investors Daily articles mentioning BIAFW.
Stock researchCompany · Overview
BIAFW research
Overview
Company profile and research snapshot.
Company profile
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Sep 5, 2026
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right?
bioAffinity Technologies jumped 47.95% on September 2, one day after announcing that it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The move followed a 1-for-15 reverse split that became effective for trading on August 24, a combination that can produce dramatic percentage swings in a thinly traded stock. […]
Yahoo · Sep 3, 2026
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN ANTONIO, September 03, 2026--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
Yahoo · Sep 3, 2026
bioAffinity Technologies Shares Rise After CyPath Lung Surveillance Update
bioAffinity Technologies (NASDAQ:BIAF) shares rose 39. 4% in premarket trading after the company announced that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance of lung cancer recurrence.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
